Biosimilars and Access: How Trastuzumab Competition Is Reshaping...

added article Health

2026-10-23 05:56:58 -

Trastuzumab, the monoclonal antibody that revolutionized HER2 positive breast cancer treatment, is now available as multiple biosimilars—biologically similar versions that offer comparable safety and efficacy at lower costs. This competition has significantly expanded access to HER2-targeted therapy, particularly in markets where originator trastuzumab was previously unaffordable....

0 Comments 0 Shares 131 Views